Patent Application: Peptide Binds Trop2 for Cancer Treatment

ChangeBridge: Patent Apps - Peptides (C07K)

Published August 10th, 2023

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085091A1) from Kyungpook National University Industry-Academic Cooperation Foundation for a peptide that selectively binds to Trop 2. The peptide is intended for targeted therapeutic agents and anticancer drugs for resistant cancers such as breast, pancreatic, and cholangiocarcinoma.

View original document View source feed page

What changed

This document is a published patent application from the USPTO detailing a novel peptide (amino acid sequence: CSTLNVESC) that selectively binds to Trop 2. The application, filed by Kyungpook National University Industry-Academic Cooperation Foundation, outlines its potential use in developing targeted therapeutic agents and anticancer drugs for highly resistant cancers, including triple-negative breast cancer, pancreatic cancer, and cholangiocarcinoma.

As this is a patent application, it does not impose immediate regulatory obligations. However, companies in the pharmaceutical and biotechnology sectors involved in cancer therapeutics should monitor this application for potential future intellectual property developments and competitive landscape shifts. The application's publication date is March 26, 2026, with a filing date of August 10, 2023.

Source document (simplified)

← USPTO Patent Applications

PEPTIDES THAT SELECTIVELY BIND TO Trop2 AND USE THEREOF

Application US20260085091A1 Kind: A1 Mar 26, 2026

Assignee

KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventors

Byung-Heon LEE, Uttapol PERMPOON, Peti Thuwajit

Abstract

The present disclosure relates to a peptide binding to Trop 2 and a use thereof, wherein, in an attempt to find a peptide having an ability of specifically binding to Trop 2, a peptide (amino acid sequence: CSTLNVESC (SEQ ID NO: 1)) that selectively binds to Trop 2 was discovered using a phage display technique. Targeting cancers that are highly resistant to anticancer drugs in breast cancer (in particular, triple-negative breast cancer), pancreatic cancer, and cholangiocarcinoma while having no effective treatments, an effective anticancer drug may be prepared by delivering cancer-specific drugs or developing targeted therapeutic agents using the peptide of the present disclosure.